ArticleTransboundary and emerging diseases2026
Emergence of a Highly Virulent Porcine Epidemic Diarrhea Virus (PEDV) G2c Subtype in China: Isolation, Genetic and Pathogenic Characterization, and Cross-Neutralizing Antibody Response.
Article in Transboundary and emerging diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- In Vitro Assessment of Antiviral Activity of Saikosaponin B2 Against Porcine Epidemic Diarrheal Virus.Viruses · 2026Article
- Isolation, Characterization and Reverse Genetic System Establishment of a Highly Virulent PEDV Strain.Viruses · 2026Article
- Genetic Diversity and Molecular Evolution of Porcine Epidemic Diarrhea Virus in Chongqing, China (2022-2024).Animals : an open access journal from MDPI · 2026Article
- Egg Yolk Antibodies Elicited by a Novel Multi-Epitope Recombinant Adenovirus Vaccine Against Genotype G2b PEDV Spike Protein Reduce Mortality and Viral Shedding in Passively Immunized Piglets.Pathogens (Basel, Switzerland) · 2026Article
- Isolation and assessment of characterization of porcine epidemic diarrhea virus GD1 strain from China.Frontiers in veterinary science · 2026Article
- Preclinical Evaluation of a Phage T4-Based Multi-Epitope Nanoparticle Vaccine Against Porcine Epidemic Diarrhea Virus.Transboundary and emerging diseases · 2026Article
- Emergence of a Highly Virulent Porcine Epidemic Diarrhea Virus (PEDV) G2c Subtype in China: Isolation, Genetic and Pathogenic Characterization, and Cross-Neutralizing Antibody Response.Transboundary and emerging diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine epidemic diarrhea virus (PEDV), an enteropathogenic coronavirus causing high mortality in neonatal piglets, continues to threaten global swine industries. Frequent mutations in the spike (S) protein of PEDV, particularly in emerging variants, have substantially compromised commercial vaccine efficacy. Despite the emergence of G2c variants dominating recent epidemics, comprehensive studies integrating viral isolation, phylogenetics, structural modeling, cross-neutralizing antibody response, and pathogenicity assessment remain insufficient. In this study, we successfully isolated a G2c strain (AHCZ02) and obtained 69 S gene sequences from nine provinces during 2021-2024. Phylogenetic analysis identified G2c variants as predominant (69.57%, 48/69) in current outbreaks. Structural comparisons revealed four G2c-specific substitutions (N139D, I287M, F345L, and L998M) inducing conformational changes in critical S domains compared to G2a/G2b strains, potentially disrupting immune recognition. The results of serum neutralizing antibody (nAb) test using the AHCZ02 strain showed that G2c-based feedback exposure strategies elicited 3.9-fold higher geometric mean titers (GMTs) than S-INDEL-based approaches. Furthermore, feedback exposure strategies of G2c (GMT = 480-1893) showed 12- to 189.3-fold higher neutralizing activity versus conventional vaccines (GMT = 10-40). Pathogenicity assessment in neonatal piglets revealed 100% mortality within 66 h post-AHCZ02 inoculation, accompanied by hallmark clinical manifestations including profuse watery diarrhea, rapid weight loss, and severe jejunal villus atrophy. Collectively, these findings provide evidence that G2c variants have developed S protein modifications associated with diminished vaccine efficacy, underscoring the need for next-generation vaccines incorporating G2c-specific antigenic determinants, and strengthened virological surveillance systems to effectively monitor and respond to PEDV evolutionary dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.